{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T14:49:34Z","timestamp":1767451774064,"version":"build-2065373602"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Epirubicin is widely used in many malignancies with good efficacy and tolerability. However, investigations about adverse events (AEs) using real-world information are still insufficient.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We extracted Epirubicin-related reports submitted between the first quarter of 2014 and first quarter of 2023 from FAERS database. Four algorithms were utilized to evaluate whether there was a significant correlation between Epirubicin and AEs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> After de-duplicating, a total of 3919 cases were extracted. Among the 3919 cases, we identified 1472 AEs, 253 of which were found to be adverse drug reactions (ADRs) associated with Epirubicin. We analysed the occurrence of Epirubicin-induced ADRs and found several unexpected significant ADRs, such as hepatic artery stenosis, hepatic artery occlusion, intestinal atresia and so on. Interestingly, we found gait apraxia, a neurological condition, was also significantly associated with Epirubicin. To our knowledge, there haven't studies that have reported an association between gait disorders and the usage of epirubicin.<\/jats:p><jats:p><jats:bold>Discussion:<\/jats:bold> Our study identified new unexpected significant ADRs related to Epirubicin, providing new perspectives to the clinical use of Epirubicin.<\/jats:p>","DOI":"10.3389\/fphar.2023.1249845","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:13:52Z","timestamp":1694697232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database"],"prefix":"10.3389","volume":"14","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lipeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengbo","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2165\/00002018-200629100-00005","article-title":"Comparative performance of two quantitative safety signalling methods: Implications for use in a pharmacovigilance department","volume":"29","author":"Almenoff","year":"2006","journal-title":"Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","article-title":"Primary liver cancer: Worldwide incidence and trends","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: Implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1200\/JCO.2009.22.1077","article-title":"Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer","volume":"28","author":"Burnell","year":"2010","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1161246","DOI":"10.3389\/fpsyt.2023.1161246","article-title":"Detecting microstructural alterations of cerebral white matter associated with breast cancer and chemotherapy revealed by generalized q-sampling MRI","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.parkreldis.2018.02.024","article-title":"Apraxia of gait- or apraxia of postural transitions?","volume":"50","author":"Dale","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1200\/JCO.2008.17.2155","article-title":"Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study","volume":"27","author":"de Azambuja","year":"2009","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/jnnp.72.1.77","article-title":"Gait apraxia after bilateral supplementary motor area lesion","volume":"72","author":"Della Sala","year":"2002","journal-title":"J. Neurology, Neurosurg. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1200\/JCO.2011.36.8571","article-title":"Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning","volume":"30","author":"Deprez","year":"2012","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/0959-8049(95)00323-b","article-title":"Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours","author":"Ellis","year":"1995","journal-title":"Eur. J. Cancer (Oxford, Engl. 1990)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet (London, Engl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s43441-022-00415-y","article-title":"A systematic review of pharmacovigilance systems in developing countries using the WHO pharmacovigilance indicators","volume":"56","author":"Garashi","year":"2022","journal-title":"Ther. Innovation Regul. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","article-title":"Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer","volume":"21","author":"Henderson","year":"2003","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.eururo.2007.12.033","article-title":"Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer","volume":"53","author":"Hendricksen","year":"2008","journal-title":"Eur. Urol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.critrevonc.2013.07.003","article-title":"Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review","volume":"88","author":"Id\u00e9e","year":"2013","journal-title":"Crit. Rev. Oncology\/hematology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: Analysis of spontaneous reports submitted to FAERS","volume":"39","author":"Ji","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"B17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.breast.2011.12.012","article-title":"Epirubicin: Is it like doxorubicin in breast cancer? A clinical review","volume":"21","author":"Khasraw","year":"2012","journal-title":"Breastedinbg. Scotl."},{"key":"B18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jsps.2022.11.016","article-title":"Temporal offset association between the number of irinotecan-related adverse reactions and pharmacogenomic studies: A cross-correlation analysis","volume":"31","author":"Kong","year":"2023","journal-title":"Saudi Pharm. J. SPJ Official Publ. Saudi Pharm. Soc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.3390\/cancers13123091","article-title":"Hepatic arterial infusion of chemotherapy for advanced hepatobiliary cancers: State of the art","volume":"13","author":"Laface","year":"2021","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1109\/mitp.2005.122","article-title":"RxNorm: Prescription for electronic drug information exchange","volume":"7","author":"Ma","year":"2005","journal-title":"IEEE Comput. Soc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11604-007-0216-5","article-title":"Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma","volume":"26","author":"Maeda","year":"2008","journal-title":"Radiat. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.diii.2017.10.010","article-title":"Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma","volume":"98","author":"Matsui","year":"","journal-title":"Diagnostic Interventional Imaging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.diii.2017.10.010","article-title":"Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma","volume":"98","author":"Matsui","year":"","journal-title":"diagn. Interv. Imaging"},{"key":"B24","first-page":"556","article-title":"Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: A meta-analysis of randomized controlled trials","volume":"80","author":"Meng","year":"2014","journal-title":"Minerva Anestesiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/jbiol73","article-title":"How chemotherapy damages the central nervous system","volume":"7","author":"Meyers","year":"2008","journal-title":"J. Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/02841869009089998","article-title":"Current status of epirubicin (Farmorubicin) in the treatment of solid tumours","volume":"29","author":"Mouridsen","year":"1990","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"B27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e","article-title":"Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients","volume":"56","author":"Okuda","year":"1985","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2165\/00002512-199915040-00006","article-title":"Epirubicin: A review of its intravesical use in superficial bladder cancer","volume":"15","author":"Onrust","year":"1999","journal-title":"Drugs & Aging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/s0022-5347(17)36198-0","article-title":"A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J. Urology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/1120009x.1993.11739234","article-title":"Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin","volume":"5","author":"Pavone-Macaluso","year":"1993","journal-title":"J. Chemother. (Florence, Italy)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"788","DOI":"10.2165\/00003495-199345050-00011","article-title":"Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy","volume":"45","author":"Plosker","year":"1993","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: An update","volume":"38","author":"Richters","year":"2020","journal-title":"World J. Urology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40264-017-0526-1","article-title":"Evaluation of pre-marketing factors to predict post-marketing boxed warnings and safety withdrawals","volume":"40","author":"Schick","year":"2017","journal-title":"Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","article-title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"B36","first-page":"549","article-title":"Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma","volume":"35","author":"Tawada","year":"2015","journal-title":"Anticancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/B978-0-444-51892-7.00044-9","article-title":"Frontal lobe ataxia","volume":"103","author":"Thompson","year":"2012","journal-title":"Handb. Clin. Neurology"},{"key":"B38","first-page":"379","article-title":"4'-epidoxorubicin for intravesical instillation in urotheliomas of the bladder","volume":"38","author":"Tripi","year":"1986","journal-title":"Minerva Urologica E Nefrologica = Italian J. Urology Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"CD007938","DOI":"10.1002\/14651858.CD007938.pub4","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1194545","DOI":"10.3389\/fphar.2023.1194545","article-title":"Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1249845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:13:58Z","timestamp":1694697238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1249845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":40,"alternative-id":["10.3389\/fphar.2023.1249845"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1249845","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"article-number":"1249845"}}